摘要
目的观察TGF-β ⅡR单链抗体/轻链恒定区/鱼精蛋白截短体融合蛋白(简称新型载体)携带miR-29b对体外培养肝星状细胞(HSC)的转染效率和治疗效果,为今后肝纤维化基因治疗提供新裁体。方法脂质体、新型载体和慢病毒携带miR-29b治疗体外培养的HSC,荧光显微镜和流式细胞术观察转染效率,实时荧光定量RT-PCR和WesternBlot技术分析collagen αl(I)mRNA和蛋白表达水平。结果与对照组比较,慢病毒组的转染效率最高,为70%;其次为新型载体组,为58%;最后为脂质体组,为29%。各载体组collagen αl(I)mRNA表现出不同的下降,与对照组比较,慢病毒组下降70%(t=6.316,P〈0.01),新型载体组为50%(t=4.082,P〈0.01),脂质体组为38%(t=3.014,P〈0.05)。各载体组collagen αl(I)蛋白也表现出不同的下降,慢病毒组下降为59%(t=4.209,P〈0.01);新型载体组为41%(t=4.033,P〈0.01;);脂质体组为27%(t=2.842,P〈0.05)。结论笔者构建的新型载体具有较高的转染效率,并且携带miR-29b具有较好的抗肝纤维化效果。
Objective To observe the transfection efficiency and anti-fibrotic effect of miR-29b transfected by anti-TGF-β ⅡR R ScFv/Ck/tP fusion protein (new vector) in hepatic stellate cell (HSC), and to provide a new vector in gene therapy for liver fibrosis. Methods The liposome vector, new vector, and lentiviral vector were used as transfection reagents to transfect miR-29b into HSC. Transfection efficiency was observed under fluorescence microscope and flow cytometry. Collagen cd (I) mRNA and protein expres- sion in different groups were analyzed by real-time RT-PCR and Western Blot, respectively. Results Com- pared to the control, transfection efficiencies in lentiviral vector, new vector, and liposome vector groups were about 70%, 58% , and 29% , respectively. Collagen α1 (I) mRNA expression in lentiviral vector, new vector, and hposome vector groups was decreased by about 70%, 50%, and 38%, respectively ( ( t =6.316, P 〈0. 01;t =4.082, P 〈0.01;t =3.014, P 〈0.05). Collagen αl(I) protein expression in lentiviral vector, new vector, and liposome vector groups was decreased by about 59%, 41% , and 27% , respectively (t =4.209, P 〈0.01; t =4.033, P 〈0.01; t =2.842, P 〈0.05). Conclusions The new vector constructed by us has a high transfection efficiency. MiR-29b transfected by the new vector has a good anti-liver fibrosis effect.
出处
《中国医师杂志》
CAS
2012年第10期1331-1334,共4页
Journal of Chinese Physician
基金
国家自然科学基金项目(81000176,81100292)
浙江省自然科学基金项目(Y2110634,Y2090326)
王宝恩肝纤维化研究基金项目(20100002)
温州市科技局项目(Y20110033)